Bernice J A Gulpers1, Richard C Oude Voshaar2, Martin P J van Boxtel3, Frans R J Verhey3, Sebastian Köhler4. 1. MET GGZ Maastricht (BG), Regional Institute for Mental Health Care in Outpatients, Maastricht, Netherlands; Department of Psychiatry and Neuropsychology (BG, MPJvB, FRJV, SK), School for Mental Health and Neuroscience and Alzheimer Centre Limburg, Maastricht University Medical Center+, Maastricht, Netherlands. 2. Center for Psychiatry & Interdisciplinary Center of Psychopathology of Emotion Regulation (RCOV), University Medical Center Groningen, Groningen, Netherlands. 3. Department of Psychiatry and Neuropsychology (BG, MPJvB, FRJV, SK), School for Mental Health and Neuroscience and Alzheimer Centre Limburg, Maastricht University Medical Center+, Maastricht, Netherlands. 4. Department of Psychiatry and Neuropsychology (BG, MPJvB, FRJV, SK), School for Mental Health and Neuroscience and Alzheimer Centre Limburg, Maastricht University Medical Center+, Maastricht, Netherlands. Electronic address: s.koehler@maastrichtuniversity.nl.
Abstract
OBJECTIVE: Anxiety might be a risk factor for cognitive decline, but previous studies had short follow-up or small sample sizes or studied general or single cognitive domain functioning. METHODS: Anxiety symptoms were assessed with the Symptom Checklist-90 in 918 participants of the Maastricht Aging Study aged 50 years or older. Anxiety was analyzed both dichotomously (highest versus lower quartiles as a group) and continuously. Neuropsychological tests measured executive function, memory, speed of information processing, and verbal fluency. Linear mixed models were conducted with anxiety symptoms as predictor and change in cognitive scores as outcome. Differences of associations by age and gender were studied with three-way interactions. RESULTS: Higher anxiety symptoms were significantly associated with more decline in verbal memory in those aged 65 years and older (delayed recall: χ2 = 9.30, df = 2, p = 0.01; immediate recall: χ2 = 11.81, df = 2, p = 0.003). There were sex differences in executive function (χ2 = 6.63, df = 2, p = 0.036), fluency (χ2 = 6.89, df = 2, p = 0.032), and processing speed (χ2 = 8.83, df = 2, p = 0.012), with lower performance in women over time. CONCLUSION: In participants without cognitive impairments at baseline, anxiety symptoms were associated with a decline in verbal memory in older adults and with poorer performance in nonamnestic domains in women. Adequate treatment of anxiety symptoms could have a beneficial influence on the risk of developing neurodegenerative diseases. Further research is needed to elucidate whether this association is causal.
OBJECTIVE:Anxiety might be a risk factor for cognitive decline, but previous studies had short follow-up or small sample sizes or studied general or single cognitive domain functioning. METHODS:Anxiety symptoms were assessed with the Symptom Checklist-90 in 918 participants of the Maastricht Aging Study aged 50 years or older. Anxiety was analyzed both dichotomously (highest versus lower quartiles as a group) and continuously. Neuropsychological tests measured executive function, memory, speed of information processing, and verbal fluency. Linear mixed models were conducted with anxiety symptoms as predictor and change in cognitive scores as outcome. Differences of associations by age and gender were studied with three-way interactions. RESULTS: Higher anxiety symptoms were significantly associated with more decline in verbal memory in those aged 65 years and older (delayed recall: χ2 = 9.30, df = 2, p = 0.01; immediate recall: χ2 = 11.81, df = 2, p = 0.003). There were sex differences in executive function (χ2 = 6.63, df = 2, p = 0.036), fluency (χ2 = 6.89, df = 2, p = 0.032), and processing speed (χ2 = 8.83, df = 2, p = 0.012), with lower performance in women over time. CONCLUSION: In participants without cognitive impairments at baseline, anxiety symptoms were associated with a decline in verbal memory in older adults and with poorer performance in nonamnestic domains in women. Adequate treatment of anxiety symptoms could have a beneficial influence on the risk of developing neurodegenerative diseases. Further research is needed to elucidate whether this association is causal.
Authors: Elliottnell Perez; Joseph M Dzierzewski; Adrienne T Aiken-Morgan; Christina S McCrae; Matthew P Buman; Peter R Giacobbi; Beverly L Roberts; Michael Marsiske Journal: Aging Ment Health Date: 2019-09-12 Impact factor: 3.658
Authors: Márcia Maria de Souza; Marina Corrêa Andreolla; Thaís Cecília Ribeiro; Ana Elisa Gonçalves; Alex Rogério Medeiros; Anacleto Silva de Souza; Leonardo Luiz Gomes Ferreira; Adriano Defini Andricopulo; Rosendo Augusto Yunes; Aldo Sena de Oliveira Journal: RSC Med Chem Date: 2020-02-14
Authors: Jacobo Mintzer; Keaveny Anne Donovan; Arianne Zokas Kindy; Sarah Lenz Lock; Lindsay R Chura; Nicholas Barracca Journal: Front Med (Lausanne) Date: 2019-10-04
Authors: Ashley F Curtis; Anthony Schmiedeler; Madison Musich; Maggie Connell; Mary Beth Miller; Christina S McCrae Journal: Psychol Rep Date: 2022-01-31
Authors: Inger Utne; Borghild Løyland; Ellen Karine Grov; Steven Paul; Melisa L Wong; Yvette P Conley; Bruce A Cooper; Jon D Levine; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2019-07-02 Impact factor: 2.398